Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -9.50% | 7.70% | 13.86% | -14.40% | 0.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.50% | 7.70% | 13.86% | -14.40% | 0.50% |
| Cost of Revenue | -10.95% | 2.66% | 21.93% | 10.82% | 15.52% |
| Gross Profit | 5.71% | 396.48% | -39.89% | -184.07% | -11.92% |
| SG&A Expenses | -11.40% | -10.30% | -9.89% | -17.71% | -19.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.60% | -3.27% | 5.59% | -3.90% | 0.85% |
| Operating Income | 17.26% | 15.92% | 4.91% | -9.26% | -1.17% |
| Income Before Tax | 25.94% | 7.10% | 173.41% | -9.45% | -8.52% |
| Income Tax Expenses | -183.85% | 133.33% | -47.24% | 31.48% | 78.08% |
| Earnings from Continuing Operations | 26.43% | 7.05% | 172.91% | -9.48% | -8.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.43% | 7.05% | 172.91% | -9.48% | -8.65% |
| EBIT | 17.26% | 15.92% | 4.91% | -9.26% | -1.17% |
| EBITDA | 17.31% | 15.97% | 4.95% | -10.01% | -1.27% |
| EPS Basic | 32.92% | 14.92% | 152.78% | 8.35% | 14.88% |
| Normalized Basic EPS | 32.45% | 14.97% | 39.49% | -7.57% | 22.07% |
| EPS Diluted | 32.37% | 13.79% | 31.67% | 8.35% | 15.37% |
| Normalized Diluted EPS | 32.45% | 14.97% | 52.57% | -7.57% | 22.07% |
| Average Basic Shares Outstanding | 9.67% | 9.27% | 5.97% | 1.74% | 27.62% |
| Average Diluted Shares Outstanding | 9.67% | 9.27% | 35.22% | 1.74% | 27.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |